HAON Life Science’s Post

We're entering new territory at CergenX! Our first product, the CergenX Wave device, is currently being tested on newborns in a hospital environment as part of a Feasibility Study. This non-interventional, observational study is designed to assess the usability of the device. The Feasibility Study is a key element of CergenX's DTIF partnership with the INFANT Research Centre at University College Cork. The study is part of the CergenX-led consortium, which was awarded €6.7m in non-dilutive grant funding last year from Enterprise Ireland and DTIF. Recruitment for the study is progressing well, with dozens of newborns already tested. This marks a significant milestone for CergenX, elevating the company to the next level. In a short period of time, the team has transformed a promising idea into a fully realised device that is now deployed in a busy hospital setting. Wave is poised to make a meaningful impact on newborns, their families, and healthcare professionals. The entire team at CergenX is proud of this achievement—the result of 18 months of hard work and perseverance. Our special thanks are extended to the team at INFANT Research Centre and Cork University Maternity Hospital (CUMH) for their instrumental role in launching and maintaining the study, as well as to the parents who consented to their newborns participating. Cork University Hospitals Group #MedTechInnovation #BrainInjury #AiForGood